CYTADREN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYTADREN (mitotane) is an oral small-molecule adrenolytic agent approved in 1980 for treating adrenocortical carcinoma. The drug works by causing selective destruction of the adrenal cortex, reducing excess cortisol production in severe Cushing's syndrome and ACC. It is a legacy product in Novartis's specialty oncology portfolio with limited modern clinical development.
LOE Approaching
This legacy product faces moderate competitive pressure (30%) with limited linked job opportunities, suggesting a small, maintenance-focused team with minimal expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYTADREN offers limited career upside; this is a maintenance role in a niche rare-disease indication with minimal headcount and no launch momentum. Professionals should expect focus on compliance, physician relationships, and preparation for LOE rather than growth or innovation.
Product ManagerMedical Science Liaison
Worked on CYTADREN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.